⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29008787 | 1.00 | — | — | |
| SCHEMBL752056 | 1.00 | — | — | |
| SCHEMBL14473594 | 0.97 | — | — | |
| SCHEMBL14044655 | 0.97 | — | — | |
| SCHEMBL13522863 | 0.84 | — | — | |
| SCHEMBL27999995 | 0.84 | — | — | |
| SCHEMBL6726231 | 0.79 | — | — | |
| SCHEMBL28081379 | 0.79 | — | — | |
| SCHEMBL27999822 | 0.79 | — | — | |
| SCHEMBL27991708 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | claimed |
| EP-4626892-A1 | ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024118460-A1 | ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-113166062-A | 8-aminoisoquinoline compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2021-07-23 | — | — | CN | disclosed |